



CardioOncopilot

Quick Start Guide

Table of Contents

▶ Features	3
▶ First login	4
▶ Main menu	10
▶ Cardio-oncology consultation	17
▶ Administration tools	24

Disclaimer

This software may only be used for clinical research purposes by physicians practicing within the European Economic Area.

Features



Drug classes

- anthracyclines
- HER2-targeted therapies
- all classes with an HFA-ICOS score (coming in Patch 02)



ESC 2022 guidelines implemented

- risk stratification
- follow-up schedule planning
- management of complications (coming in Patch 02)



Available clinical studies




ML-CardioTox – NCT07191730



First login

Create an account (1)




The screenshot shows the CardioOncopilot account creation interface. On the left is the CardioOncopilot logo, which features a stylized pink heart with a white ECG line and two pink wings. To the right of the logo, the text "CardioOncopilot" is displayed. Further right, the header "CardioOncopilot" is followed by the tagline "For the heart, against cancer!". Below this, there are two buttons: "Connect by email" and "Create an account". The "Create an account" button is highlighted in blue. Under the heading "I am :", there are input fields for "First Name", "Last Name", "Email", "Password", and "Confirm Password". The "Password" and "Confirm Password" fields have eye icons for toggling visibility. At the bottom, there is a checkbox labeled "I agree to Privacy Policy & Terms of Use" and a large pink button labeled "CREATE AN ACCOUNT".

- Software available at cardiooncopilot.com
- Enter your identity and create your password
- Accept the privacy policy and the software terms of use

Create an account (2)

- Click on the link you received in your email
- You can now log in at cardiooncopilot.com



The screenshot shows the CardioOncopilot website interface. On the left is the CardioOncopilot logo, which features a stylized red heart with two small circles above it, flanked by two red wings or arms, with the text "CardioOncopilot" below. On the right, the text "CardioOncopilot" is followed by the tagline "For the heart, against cancer!". Below this are two buttons: "Connect by email" (blue) and "Create an account" (light blue). Underneath these are input fields for "Email" and "Password" (with an eye icon for toggling visibility). A red "LOG IN" button is positioned below the password field. At the bottom right, there is a link for "Forgot password". A small red flag icon with a white cross is visible in the top right corner of the page.

Create an account (3)

Securing your account

1. Download Google Authenticator or Microsoft Authenticator on your phone.

2. Scan this QR Code (valid for 1 hour)



Cannot scan the QR Code?
Reveal your secret key by clicking on it and enter it manually in the app

3. Enter the 6-digit code

Ex: 1 2 3 4 5 6 



Two-factor authentication


- Use Google Authenticator or Microsoft Authenticator on your phone
- Scan the QR code in the application
- Enter the 6-digit code



This code changes every 30 seconds. You will need to enter it each time you log in to CardioOncoPilot.


Join an organization (1)

To use CardioOncoPilot, you **must** be affiliated with at least one organization. This may be a hospital or a medical practice.

A screenshot of a web application interface. At the top left, there is a blue link that says '← LOG OUT'. At the top right, there is a small red cross icon with a dropdown arrow. The main heading is 'You don't belong to any organisation'. Below this is a search input field with the placeholder text 'Which organisation are you part of ?'. Underneath the input field, there is a small note: 'Note : If you have already made a request, wait for one of the organisation's administrators to accept your request'. At the bottom of the form, there is a grey button with a mail icon and the text 'ASK TO JOIN'.

Search for your organization in the field using the search engine and request to join the organization.

Join an organization (2)




For security reasons, you will not have immediate access, **your request must be approved by your institution's administrator.**

🎉 After validation by your institution's administrator, you will have access to the center's patients and can begin creating consultations.

⚠️ *If you cannot find your organization, contact us at **contact@cardiooncopilot.com** so we can create it.*




Main menu




1. **Search for an existing patient** to create a consultation
2. **Create a new patient** before starting the consultation
3. **View the latest consultations performed**

Organization menu



1. Shows the **organization you are currently connected to**
2. **Leave this organization** (⚠️ this action is permanent)
3. **Switch organization** (if you belong to multiple organizations)
4. **Request to join a new organization** (if you work across multiple sites)



The screenshot shows a clinical study interface for 'ML CardioTex'. It includes a sidebar with navigation icons, a main content area with study details, and a bottom section for patient lists.

ML CardioTex
From January 1, 2024 to December 31, 2027
Follow-up duration: 365 days

Sponsor: Coen University Hospital (CHU de Coen)

Objectives

- **Primary:** Develop a machine learning prediction score for the 1-year risk of cardiotoxicity in a consecutive cohort of patients referred to a cardio-oncology clinic for a pre-therapy assessment prior to treatment with anthracyclines and/or anti-HER2 therapy.
- **Secondary:**
 - Identify prognostic factors involved in the occurrence of cardiovascular toxicity
 - Compare the performance of the machine learning prediction score with the IFA-ICD5 adverse event risk stratification score described in the 2022 ESC guidelines

Inclusion criteria

- Age > 18 years
- Cardio-oncology follow-up planned as part of the pre-therapy assessment of a treatment sequence with anthracyclines and/or anti-HER2 therapy, in accordance with the 2022 ESC guideline recommendations


Non-inclusion criteria

- Patient not covered by a Social Security scheme
- Patient for whom the 12-month follow-up is planned outside the center that performed the pre-therapy assessment

The clinical studies in which your organization participates are displayed here. For each study, you can view the objectives, the main inclusion and exclusion criteria, and the list of patients from your organization currently being followed.

 While you are seeing a patient in consultation, if we determine that the patient appears to be eligible for one of the clinical studies in which your organization is participating as an investigational site, you will be notified.

Patients menu



CHU de Caen
Damien LEGALLOIS

Patients 2 

1 Search a patient (Last name, First name, Date of birth)

Last name	First name	Date of birth	Age
		March 9, 1990	36
		March 6, 1956	70
		May 12, 1963	63
		April 4, 1941	85
		March 17, 1968	58
		November 27, 1975	50
		May 28, 1982	44

3

1. **Filter the patient list**
2. **Patient list:** clicking on a patient opens their record (see next page)
3. **Create a new patient**

Patients menu > Patient record

 **CHATRE Lucien**
3/17/1968

identity

Last name CHATRE	First name Lucien
Date of birth 03/17/1968	Gender Male

[UPDATE](#)

Last consultations of CHATRE Lucien


7/4/2026
Lucien CHATRE


1/24/2026
Lucien CHATRE

consultation history

[+ START A CONSULTATION](#) [SEE ALL](#)

Ongoing studies for this patient

MLCardioTox	May 1, 2026	
-------------	-------------	---

inclusion in a clinical research protocol



consultation started but not completed; click to resume it



consultation completed



[+ START A CONSULTATION](#)

create a new follow-up consultation



download the PDF
open in a new tab



view the PDF

Consultations menu

Creation date	Last name	First name	Created by	Compl...
July 5, 2026			LEGALLOIS Damien	○
July 4, 2026			LEGALLOIS Damien	○
July 4, 2026			LEGALLOIS Damien	○
July 4, 2026			LEGALLOIS Damien	○
June 18, 2026			JAIME Quentin	○
June 18, 2026			JAIME Quentin	○
June 12, 2026			DOLLADILLE Charles	●

The most recent consultations are at the top of the list, the ○ logo indicates that the report has not been finalized. You can return to it by clicking on it.



Cardio-oncology consultation

The **consultation screen** can be accessed either after creating a new patient or by clicking the button to create a follow-up consultation for an already registered patient (page 15).

The consultation screen is divided into two sections:

- **on the left, the input fields** (page 19)
- **on the right, the report preview** (page 21)

Cardio-oncology consultation: left section

The screenshot shows the left section of a digital form for a cardio-oncology consultation. At the top, it displays the patient's name 'Mr Jean DUPONT (Born on October 12, 1956), 69 years' and the date 'July 5, 2026'. Below this is a 'Reason for the consultation' section with a dropdown menu set to 'Pre-therapeutic assessment' and a 'Drug*' field. The 'Context' section follows, containing three dashed boxes: 'Oncological summary' with a text field, 'Cardiovascular medical history' with three icons (heart, brain, and a third icon) and a text field set to 'none', and 'Cardiovascular risk factors' with five icons (heart, cigarette, burger, pills, and people) and three text fields for 'Weight(kg)*' (80), 'Height(cm)*' (170), and 'BMI (kg/m²)' (27.7). A vertical sidebar on the left contains icons for home, search, and other functions.

Mr Jean DUPONT (Born on October 12, 1956), 69 years
July 5, 2026

Reason for the consultation

Reason*
Pre-therapeutic assessment

Drug*

Context

Oncological summary

Oncological summary *

Cardiovascular medical history

Cardiovascular medical history
none

Cardiovascular risk factors

Weight(kg)*
80

Height(cm)*
170

BMI (kg/m²)
27.7

Select the **reason for consultation**, the **cancer medications**, and enter the patient's **medical history** and **cardiovascular risk factors**.

The software will then adapt the rest of the form to display the essential information to be collected.

The information entered on the left side of the screen is used to generate the report preview on the right side of the screen.

⚠ Fields marked with an * are mandatory.

Cardio-oncology consultation: left section

The consultation follows a structured pathway depending on the clinical situation.

Reason for the consultation

Reason*

Pre

Dru

Context

Oncological summary

Onc

Card

Associa

Can

Cardiovascular

Weight(kg)*

SCORE 2 risk

Functional signs

Clinical signs

Blood pressure

SBP* DBP*

Blood pressure (Specify)

Self-measurement

Weight(kg) Weight (Specify)

Heart sounds

Signs of left heart failure Signs of right heart failure

Peripheral pulse

Biology

Biology date

MM/DD/YYYY

Herr

Plab

Ser

Ser

Live

TSH

Ca

Triglycerides(g/L) Total cholesterol(g/L)

HDL cholesterol(g/L) Non-HDL cholesterol(g/L)

LDL cholesterol(g/L)

ECG

Rhythm*

Echocardiography

Date of echocardiography

MM/DD/YYYY

LVEF

RIVS $\geq$ 12mm

GLS

Events during consultation

Cardio-oncology consultation: right section

The right side of the screen displays the information entered on the left and formats it to provide a preview of the report.

Example below with functional symptoms:

Functional signs

Dyspnea (Specify)
NYHA II

Associated functional signs
no associated functional symptoms

Level of physical activity
walking 20 min x 3 per week



Functional signs :

Dyspnea : NYHA II. No chest pain. No palpitations. No loss of consciousness. No lower limb pain. Moreover, no associated functional symptoms. Level of physical activity : walking 20 min x 3 per week.



Save your report



Complete data entry and display the recommendations

Recommendations and clinical trial eligibility

REPORT & RECOMMENDATIONS

STUDIES

Anthracines

Recommendation for these drugs

Risk stratification

The patient is considered to be at moderate risk for anthracycline-induced cardiotoxicity.

Biomarkers

Measurement of natriuretic peptides and cardiac troponin should be considered.
baseline
in moderate-risk patients prior to anthracycline chemotherapy

Cardiac troponin and natriuretic peptides monitoring should be considered.
every 2 cycles
in patients at moderate risk receiving anthracyclines

Cardiac troponin and natriuretic peptides monitoring should be considered.
within 3 months after completing treatment
in patients at moderate risk receiving anthracyclines

TTE

Baseline echocardiography is recommended.
baseline
in all patients with cancer before anthracycline chemotherapy

Additional echocardiography should be considered.
after a cumulative dose of ≥ 250 mg/m² of doxorubicin or equivalent
in patients at moderate risk receiving anthracyclines

Echocardiography is recommended.
within 12 months after completing treatment
in all patients receiving anthracycline chemotherapy

Toxicity

CHU CAEN NORMANDIE

CONSULTATIONS DE CARDIO-ONCO-PHARMACOLOGIE

Coordinateurs de la Filière PICARO :
Pr Joachim ALEXANDRE (PU-PH) Dr Angélique DA SILVA (PH)
cardiologue et pharmacologue onco et pharmacologue
alexandre.j@chu-caen.fr dsilva.a@chu-caen.fr

Praticiens :
Dr Anne-Flore PLANE (PH) cardiologue, aplane@chu-caen.fr
Dr Charles DOLLADILLE (MCU-PH) cardiologue et pharmacologue, dolladille.c@chu-caen.fr
Dr Damien LEGALLOIS (MCU-PH) cardiologue, damien.legallois@un-caen.fr

Secrétariat et contact : Anne Nadège MONTAGNE
Tél: 02.31.06.46.70, Fax: 02.31.06.46.73, Mail: picaro@chu-caen.fr

In on July 5, 2026

I see in consultation Mr Jean DUPONT Born on October 12, 1956 (69 years old), for Pre-therapeutic assessment under Anthracyclines.

Oncological summary :
lymphoma

Cardiovascular medical history :
none

Cardiovascular risk factors :
- HighBlood pressure.
- BMI : 27.7 kg/m² (80kg for 170cm).

Other medical history :
none

Treatments : ramipril, lercanidipine

Lifestyle : lives with a partner

Functional signs :
Dyspnea : NYHA II. No chest pain. No palpitations. No loss of consciousness. No lower limb pain.

Clinically, the blood pressure is at 140 / 80 mmHg. The weight is 80kg.

QRS : Rhythm : Sinus Rhythm. Heart rate at 85 /min. PR = 180 ms. QRS at 90 ms. Measured QT : 420

VALIDATE AND DOWNLOAD THE PDF

Quick Start Guide

Patch 01 - June 2026

22 / 27



Recommendations and clinical trial eligibility

- 1 Studies for which this patient is eligible**
- 2 Filter recommendations by medication**
- 3 HFA-ICOS risk stratification** (if the therapeutic class is eligible)
- 4 Details of cardiotoxicity risk stratification**
- 5 Recommendations.** Left click = copy recommendation
- 6 Expected toxicities of cancer treatment**
- 7 Consultation letter**




Disclaimer


You can edit the text, but the changes will not be saved in the database and will therefore not be carried over to follow-up consultations. Except for the conclusion, you should therefore modify the data on the previous page instead.

- 8 Validate the letter and download the PDF.** You can always modify this letter later by accessing it again.

Administration tools

Administrators have access to the organization settings, available in the organization menu.





The screenshot shows the 'Administration tools' interface. On the left is a blue sidebar with icons for home, reports, users, and documents. The main content area has a light gray background. At the top, a white box contains a large red '1' and a red icon of a document with a plus sign, with the text 'Add a header to the reports of this organisation'. Below this is a form for organization details. The 'Organisation name' field contains 'CH de Lisleux'. The 'Address' section is enclosed in a dashed border and contains fields for 'Street' (Rue des Petites Marettes), 'City' (Magny la Campagne - Mezidon), and 'Country' (France). A 'Zip code' field contains '14270'. A large red '2' is placed over the 'City' field. Below the address fields is a blue 'UPDATE' button with a pencil icon. At the bottom, a white box titled 'Members' lists two members: 'DUPONT Marc' and 'LEGALLOIS Damien'. A large red '3' is placed over the member list. To the right of the member list is a red '4' followed by three dots. In the top right corner of the 'Members' box is the text 'See requests' followed by a large red '5'.

1 Add a header to the reports of this organisation

Organisation name
CH de Lisleux

Address

Street
Rue des Petites Marettes

City
Magny la Campagne - Mezidon

Country
France

Zip code
14270

UPDATE

Members

DUPONT Marc

LEGALLOIS Damien

See requests

- 1 Header of your center**
- 2 Contact details of your organization**
- 3 User list.** The  symbol indicates that this person has administrator rights.
- 4 Modify user permissions :** grant/remove administrator rights or revoke access rights

 Disclaimer

Deleting a user is permanent.

- 5 Organization join requests :** approve or decline a user's request to join your organization

 Disclaimer

Make sure that the person requesting to join your organization is a member of your team.



contact@cardiooncopilot.com